Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

VRTX

Market Cap$125.74B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Vertex Pharmaceuticals, Inc.Vertex Pharmaceuticals, Inc.-235.1--3%11.70.1

Earnings Call Q4 2024

February 10, 2025 - AI Summary

Strong Revenue Growth: Vertex Pharmaceuticals reported fourth quarter 2024 total product revenue of $2.91 billion, a 16% increase year-over-year. Full-year revenue reached $11.02 billion, reflecting 12% growth compared to 2023, highlighting the company’s consistent strong performance and double-digit growth for the past ten years.
New Product Launches: The company successfully launched JOURNAVX, the first oral non-opioid pain signal inhibitor, and ALYFTREK, a new CFTR modulator for cystic fibrosis. The approval of these products is significant as JOURNAVX represents a new treatment pathway for acute pain, with an expected addressable market of 80 million patients in the U.S. alone.
Pipeline Advancements: Vertex is advancing its clinical pipeline with several pivotal studies, including those for type 1 diabetes, IgAN, and AMKD. The company anticipates key enrollment milestones in 2025, with multiple Phase 3 studies ongoing. This focus on innovation is supported by substantial R&D investment, indicating potential for future revenue growth in various therapeutic areas.

Exclusive for Stockcircle Pro members

Sign upSign Up
$487.00

Target Price by Analysts

0.7% downsideVertex Pharmaceuticals Target Price DetailsTarget Price
$533.69

Current Fair Value

8.8% upside

Undervalued by 8.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$125.74 Billion
Enterprise Value$123.29 Billion
Dividend Yield$0 (0%)
Earnings per Share$-2.08
Beta0.51
Outstanding Shares257,500,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-235.14
PEG4082.58
Price to Sales11.68
Price to Book Ratio7.79
Enterprise Value to Revenue11.19
Enterprise Value to EBIT-699.3
Enterprise Value to Net Income-231
Total Debt to Enterprise0.02
Debt to Equity0.13

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Vertex Pharmaceuticals, Inc.

CEO: Jeffrey Leiden